Markers of Primary Chemoresistance of Epithelial Ascites Cells in Patients with Ovarian Cancer Guidelines for Practitioners

Abstract

Determined the primary chemoresistance markers (expression of genes ERCC1, TOP2a and ABCB1) in epithelial cells of ascites 32 primary patients with verified ovarian cancer using RT-PCR. After standard chemotherapy by the AR scheme (cisplatin+doxoru-bicin), the relapse-free survival of patients was assessed by Kaplan-Mayer. Patients with early (up to 6 months) and late (more than 6 months) relapse were isolated. As a result of the conducted studies it was established that early relapse occurred in 67% of the examined patients (the relapse-free period was 88.7+13.3 days). At the same time, in the groups with increased expression, the relapse-free period did not differ significantly, there were early relapses. The use of the Cochrane Q-test has allowed to establish that the reduced levels of ERCC1 and ABCB1, the proportion of survivors is to 72.7% (p<0.157 inch); decrease in ERCC1 and increased TOP2a increases the probability of survival to 75%; reduction of ERCC1 and reduced TOP2a determines the probability of survival of 69.2% (p<0.157 inch). Therefore, to predict the possible response to standard chemotherapy by the AR scheme in ascitic ovarian cancer, it is advisable in the epithelial cells of ascites to evaluate the expression of 2 parameters - ERCC1 and ABCB1.